Notícias e Atividades da Kymera Therapeutics

Kymera Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Kymera Therapeutics é uma empresa listada sob o símbolo KYMR (US).

Veja o organograma con seus 27 executivos principais

Biografias mais buscadas da Kymera Therapeutics

• Nello Mainolfi, Director, President and Chief Executive Officer
• Pamela Esposito, Director
• Gorjan Hrustanovic, Director

Recentes movimentos de executivos em Kymera Therapeutics

• Anna Tallman, ingressou na Companhia como Vice President, Medical Affairs  (Notícia publicada em 21 de maio de 2025).
• Noah Goodman, ingressou na Companhia como Chief Business Officer  (Notícia publicada em 10 de abril de 2025).

Criar um alerta
para seguir os movimentos de executivos da Kymera Therapeutics.

Kymera Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of Verve Therapeutics  (publicado em 17 de junho de 2025).
• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Kymera Therapeutics

• Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine | Kymera Therapeutics, Inc.
• Press Releases | Kymera Therapeutics, Inc.
• Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma | Kymera Therap
• Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma | Kymera Therapeutics, Inc.
• Kymera Therapeutics to Participate in Upcoming September Investor Conferences | Kymera Therapeutics, Inc.
• Kymera Therapeutics to Report Second Quarter 2022 Results on August 9 | Kymera Therapeutics, Inc.
• Press Releases | Kymera Therapeutics, Inc.
• Press Releases | Kymera Therapeutics, Inc.
• Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan | Kymera Therapeutics, Inc.
• Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413 | Kymera Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Kymera Therapeutics

• Kymera Therapeutics na Wikipedia, Google News e Yahoo Finance
• Kymera Therapeutics na LinkedIn, Twitter e YouTube